A targeted review of the neurobiology and genetics of behavioural addictions: An emerging area of research

Canadian Journal of Psychiatry

Volumn 58, Issue 5, 2013, Pages 260-273

  Leeman, Robert F ^a   Potenza, Marc N ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Frontal areas; Gambling; Internet use; Kleptomania; Neuroimaging; Serotonin; Sexual behaviour; Shopping; Striatum; Video games

Indexed keywords

ADDICTION; BRAIN FUNCTION; FAMILY HISTORY; GAMBLING; GENETICS; GRAY MATTER; HERITABILITY; HUMAN; INTERNET; KLEPTOMANIA; MEDICAL RESEARCH; NEUROBIOLOGY; RECREATION; REVIEW; SEROTONINERGIC SYSTEM; SEXUAL BEHAVIOR; SHOPPING; SUBSTANCE ABUSE; SYSTEMATIC REVIEW;

EID: 84878340296     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674371305800503     Document Type: Review

References (174)

1. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders. 4th ed. Text revision. Washington (DC): APA; 2000.
2. Frascella J, Potenza MN, Brown LL, et al. Shared brain vulnerabilities open the way for nonsubstance addictions: carving addiction at a new joint? Ann N Y Acad Sci. 2010;1187: 294-315.
3. Holden C. 'Behavioral' addictions: do they exist? Science. 2001;294(5544): 980-982.
4. Holden C. Behavioral addictions debut in proposed DSM-V. Science. 2010;327(5968):935.
5. Karim R, Chaudhri P. Behavioral addictions: an overview. J Psychoactive Drugs. 2012;44(1): 5-17.
6. Potenza MN. Should addictive disorders include non-substancerelated conditions? Addiction. 2006;101: 142-151.
7. Potenza MN. The neurobiology of pathological gambling and drug addiction: an overview and new findings. Philos Trans R Soc Lond B Biol Sci. 2008;363(1507): 3181-3189.
8. Nestler EJ. Is there a common molecular pathway for addiction? Nat Neurosci. 2005;8(11): 1445-1449.
9. Crabbe JC. Consilience of rodent and human phenotypes relevant for alcohol dependence. Addict Biol. 2010;15(2): 103-108. Editorial.
10. Leeman RF, Heilig M, Cunningham CL, et al. Ethanol consumption: how should we measure it? Achieving consilience between human and animal phenotypes. Addict Biol. 2010;15(2): 109-124.
11. Potenza MN. The importance of animal models of decision making, gambling, and related behaviors: implications for translational research in addiction. Neuropsychopharmacology. 2009;34(13): 2623-2624.
12. Zeeb FD, Robbins TW, Winstanley CA. Serotonergic and dopaminergic modulation of gambling behavior as assessed using a novel rat gambling task. Neuropsychopharmacology. 2009;34(10): 2329-2343.
13. Shaffer HJ. Strange bedfellows: a critical view of pathological gambling and addiction. Addiction. 1999;94(10): 1445-1448.
14. Grant J, Potenza M. The Oxford handbook of impulse control disorders. New York (NY): Oxford University Press; 2012.
15. Lobo DS, Kennedy JL. Genetic aspects of pathological gambling: a complex disorder with shared genetic vulnerabilities. Addiction. 2009;104(9): 1454-1465.
16. Potenza MN, Steinberg MA, Mclaughlin SD, et al. Gender-related differences in the characteristics of problem gamblers using a gambling helpline. Am J Psychiatry. 2001;158(9): 1500-1505.
17. Brewer JA, Potenza MN. The neurobiology and genetics of impulse control disorders: relationships to drug addictions. Biochem Pharmacol. 2008;75(1): 63-75.
18. Leeman RF, Potenza MN. Similarities and differences between pathological gambling and substance use disorders: a focus on impulsivity and compulsivity. Psychopharmacology. 2012;219(2): 469-490.
19. Barrot M, Olivier JD, Perrotti LI, et al. CREB activity in the nucleus accumbens shell controls gating of behavioral responses to emotional stimuli. Proc Natl Acad Sci U S A. 2002;99(17): 11435-11440.
20. Avena NM, Hoebel BG. A diet promoting sugar dependency causes behavioral cross-sensitization to a low dose of amphetamine. Neuroscience. 2003;122(1): 17-20.
21. Avena NM, Hoebel BG. Amphetamine-sensitized rats show sugarinduced hyperactivity (cross-sensitization) and sugar hyperphagia. Pharmacol Biochem Behav. 2003;74(3): 635-639.
22. Chambers RA, Taylor JR, Potenza MN. Developmental neurocircuitry of motivation in adolescence: a critical period of addiction vulnerability. Am J Psychiatry. 2003;160(6): 1041-1052.
23. Everitt BJ, Robbins TW. Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci. 2005;8(11): 1481-1489.
24. Jentsch JD, Taylor Jr. Impulsivity resulting from frontostriatal dysfunction in drug abuse: implications for the control of behavior by reward-related stimuli. Psychopharmacology (Berl). 1999;146(4): 373-390.
25. Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology. 2010;35(1): 217-238.
26. Arnsten AF. Catecholamine and second messenger influences on prefrontal cortical networks of "representational knowledge": a rational bridge between genetics and the symptoms of mental illness. Cereb Cortex. 2007;17(Suppl 1):i6-i15.
27. Kendler KS, Chen XN, Dick D, et al. Recent advances in the genetic epidemiology and molecular genetics of substance use disorders. Nat Neurosci. 2012;15(2): 181-189.
28. Potenza MN, Xian H, Shah K, et al. Shared genetic contributions to pathological gambling and major depression in men. Arch Gen Psychiatry. 2005;62(9): 1015-1021.
29. Slutske WS, Eisen S, True WR, et al. Common genetic vulnerability for pathological gambling and alcohol dependence in men. Arch Gen Psychiatry. 2000;57(7): 666-673.
30. Giddens JL, Xian H, Scherrer JF, et al. Shared genetic contributions to anxiety disorders and pathological gambling in a male population. J Affect Disord. 2011;132(3): 406-412.
31. Hodgins DC, Stea JN, Grant JE. Gambling disorders. Lancet. 2011;378(9806): 1874-1884.
32. Leeman RF, Potenza MN. Impulse control disorders in Parkinson's disease: clinical characteristics and implications. Neuropsychiatry (London). 2011;1(2): 133-147.
33. Leeman RF, Billingsley BE, Potenza MN. Impulse control disorders in Parkinson's disease: background and update on prevention and management. Neurodegener Dis Manag. 2012;2(4): 389-400.
34. Potenza MN, Steinberg MA, Skudlarski P, et al. Gambling urges in pathological gambling: a functional magnetic resonance imaging study. Arch Gen Psychiatry. 2003;60(8): 828-836.
35. Goudriaan AE, De Ruiter MB, Van Den Brink W, et al. Brain activation patterns associated with cue reactivity and craving in abstinent problem gamblers, heavy smokers and healthy controls: an fMRI study. Addict Biol. 2010;15(4): 491-503.
36. Crockford DN, Goodyear B, Edwards J, et al. Cue-induced brain activity in pathological gamblers. Biol Psychiatry. 2005;58(10): 787-795.
37. Potenza MN, Leung HC, Blumberg HP, et al. An fMRI stroop task study of ventromedial prefrontal cortical function in pathological gamblers. Am J Psychiatry. 2003;160(11): 1990-1994.
38. Reuter J, Raedler T, Rose M, et al. Pathological gambling is linked to reduced activation of the mesolimbic reward system. Nat Neurosci. 2005;8(2): 147-148.
39. Tanabe J, Thompson L, Claus E, et al. Prefrontal cortex activity is reduced in gambling and nongambling substance users during decision-making. Hum Brain Mapp. 2007;28(12): 1276-1286.
40. Balodis IM, Kober H, Worhunsky PD, et al. Diminished frontostriatal activity during processing of monetary rewards and losses in pathological gambling. Biol Psychiatry. 2012;71(8): 749-757.
41. Miedl SF, Fehr T, Meyer G, et al. Neurobiological correlates of problem gambling in a quasi-realistic blackjack scenario as revealed by fMRI. Psychiatry Res. 2010;181(3): 165-173.
42. Power Y, Goodyear B, Crockford D. Neural correlates of pathological gamblers preference for immediate rewards during the Iowa Gambling Task: an fMRI study. J Gambl Stud. 2012;28(4): 623-636.
43. Pallanti S, Haznedar MM, Hollander E, et al. Basal ganglia activity in pathological gambling: a fluorodeoxyglucose-positron emission tomography study. Neuropsychobiology. 2010;62(2): 132-138.
44. Linnet J, Moller A, Peterson E, et al. Inverse association between dopaminergic neurotransmission and Iowa Gambling Task performance in pathological gamblers and healthy controls. Scand J Psychol. 2011;52(1): 28-34.
45. Linnet J, Moller A, Peterson E, et al. Dopamine release in ventral striatum during Iowa Gambling Task performance is associated with increased excitement levels in pathological gambling. Addiction. 2011;106(2): 383-390.
46. Potenza MN, Walderhaug E, Henry S, et al. Serotonin 1B receptor imaging in pathological gambling. World J Biol Psychiatry. 2011 Sep 22; Epub ahead of print.
47. De Greck M, Enzi B, Prösch U, et al. Decreased neuronal activity in reward circuitry of pathological gamblers during processing of personal relevant stimuli. Hum Brain Mapp. 2010;31(11): 1802-1812.
48. Habib R DM. Neurobehavioral evidence for the "near miss" effect in pathological gamblers. J Exp Anal Behav. 2010(93): 313-328.
49. Van Holst RJ, Veltman DJ, Büchel C, et al. Distorted expectancy coding in problem gambling: is the addictive in the anticipation? Biol Psychiatry. 2012;71(8): 741-748.
50. De Ruiter MB, Veltman DJ, Goudriaan AE, et al. Response perseveration and ventral prefrontal sensitivity to reward and punishment in male problem gamblers and smokers. Neuropsychopharmacology. 2009;34(4): 1027-1038.
51. de Ruiter MB, Oosterlaan J, Veltman DJ, et al. Similar hyporesponsiveness of the dorsomedial prefrontal cortex in problem gamblers and heavy smokers during an inhibitory control task. Drug Alcohol Depend. 2012;121(1-2): 81-89.
52. Verdejo-Garcia A, Lawrence AJ, Clark L. Impulsivity as a vulnerability marker for substance-use disorders: review of findings from high-risk research, problem gamblers and genetic association studies. Neurosci Biobehav Rev. 2008;32(4): 777-810.
53. Joutsa J, Saunavaara J, Parkkola R, et al. Extensive abnormality of brain white matter integrity in pathological gambling. Psychiatry Res. 2011;194(3): 340-346.
54. Yip SW, Lacadie C, Xu J, et al. Reduced genual corpus callosal white matter integrity in pathological gambling and its relationship to alcohol abuse or dependence. World J Biol Psychiatry. 2011 May 5; Epub ahead of print.
55. Blum K, Sheridan PJ, Wood RC, et al. The D2 dopamine receptor gene as a determinant of reward deficiency syndrome. J R Soc Med. 1996;89(7): 396-400.
56. Joutsa J, Johansson J, Niemelä S, et al. Mesolimbic dopamine release is linked to symptom severity in pathological gambling. Neuroimage. 2012;60(4): 1992-1999.
57. Zack M, Poulos CX. Amphetamine primes motivation to gamble and gambling-related semantic networks in problem gamblers. Neuropsychopharmacology. 2004;29(1): 195-207.
58. Zack M, Poulos CX. A D2 antagonist enhances the rewarding and priming effects of a gambling episode in pathological gamblers. Neuropsychopharmacology. 2007;32(8): 1678-1686.
59. Tremblay A-M, Desmond RC, Poulos CX, et al. Haloperidol modifies instrumental aspects of slot machine gambling in pathological gamblers and healthy controls. Addict Biol. 2011;16(3): 467-484.
60. Fong T, Kalechstein A, Bernhard B, et al. A double-blind, placebo-controlled trial of olanzapine for the treatment of video poker pathological gamblers. Pharmacol Biochem Behav. 2008;89(3): 298-303.
61. Mcelroy SL, Nelson E, Welge J, et al. Olanzapine in the treatment of pathological gambling: a negative randomized placebo-controlled trial. J Clin Psychiatry. 2008;69(3): 433-440.
62. Pallanti S, Bernardi S, Allen A, et al. Serotonin function in pathological gambling: blunted growth hormone response to Sumatriptan. J Psychopharmacol. 2010;24(12): 1802-1809.
63. Decaria CM, Begaz T, Hollander EH. Serotonergic and noradrenergic function in pathological gambling. CNS Spectr. 1998;3: 38-45.
64. Marazziti D, Golia F, Picchetti M, et al. Decreased density of the platelet serotonin transporter in pathological gamblers. Neuropsychobiology. 2008;57(1-2): 38-43.
65. Nordin C, Ecklundh T. Altered CSF 5-HIAA disposition in pathological male gamblers. CNS Spectr. 1999;4: 25-33.
66. Pallanti S, Bernardi S, Quercioli L, et al. Serotonin dysfunction in pathological gamblers: increased prolactin response to oral m-CPP versus placebo. CNS Spectr. 2006;11: 956-964.
67. Bullock SA, Potenza MN. Pathological gambling: neuropsychopharmacology and treatment. Curr Psychopharmacol. 2012;1: 67-85.
68. Blanco C, Petkova E, Ibanez A, et al. A pilot placebo-controlled study of fluvoxamine for pathological gambling. Ann Clin Psychiatry. 2002;14(1): 9-15.
69. Hollander E, Decaria CM, Finkell JN, et al. A randomized doubleblind fluvoxamine/placebo crossover trial in pathological gambling. Biol Psychiatry. 2000;47: 813-817.
70. Kim SW, Grant JE, Adson DE, et al. A double-blind, placebocontrolled study of the efficacy and safety of paroxetine in the treatment of pathological gambling disorder. J Clin Psychiatry. 2002;63: 501-507.
71. Grant JE, Kim SW, Potenza MN, et al. Paroxetine treatment of pathological gambling: a multi-center randomized controlled trial. Biol Psychiatry. 2003;53(8):200s-200s.
72. Saiz-Ruiz J, Blanco C, Ibáñez A, et al. Sertraline treatment of pathological gambling: a pilot study. J Clin Psychiatry. 2005;66(1): 28-33.
73. Grant JE, Potenza MN, Hollander E, et al. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry. 2006;163(2): 303-312.
74. Grant JE, Kim SW, Hartman BK. A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges. J Clin Psychiatry. 2008;69(5): 783-789.
75. Grant JE, Odlaug BL, Potenza MN, et al. Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study. Br J Psychiatry. 2011;197(4): 330-331.
76. Kim SW, Grant JE, Adson DE, et al. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry. 2001;49(11): 914-921.
77. Toneatto T, Brands B, Selby P. A randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of concurrent alcohol use disorder and pathological gambling. Am J Addict. 2009;18: 219-225.
78. Grant JE, Kim SW, Odlaug BL. N-acetyl cysteine, a glutamatemodulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry. 2007;62: 652-657.
79. Grant JE, Chamberlain SR, Odlaug BL, et al. Memantine shows promise in reducing gambling severity and cognitive inflexibility in pathological gambling: a pilot study. Psychopharmacology. 2010;212: 603-612.
80. Roy A, Adinoff B, Roehrich L, et al. Pathological gambling. A psychobiological study. Arch Gen Psychiatry. 1988;45(4): 369-373.
81. Roy A, De Jong J, Linnoila M. Extraversion in pathological gamblers. Correlates with indexes of noradrenergic function. Arch Gen Psychiatry. 1989;46(8): 679-681.
82. Meyer G, Schwertfeger J, Exton MS, et al. Neuroendocrine response to casino gambling in problem gamblers. Psychoneuroendocrinology. 2004;29(10): 1272-1280.
83. Pallanti S, Bernardi S, Allen A, et al. Noradrenergic function in pathological gambling: blunted growth hormone response to clonidine. J Psychopharmacol. 2010;24(6): 847-853.
84. Slutske WS, Zhu G, Meier MH, et al. Genetic and environmental influences on disordered gambling in men and women. Arch Gen Psychiatry. 2010;67(6): 624-630.
85. Blanco C, Myers J, Kendler KS. Gambling, disordered gambling and their association with major depression and substance use: a web-based cohort and twin-sibling study. Psychol Med. 2012;42(03): 497-508.
86. Shah KR, Eisen SA, Xian H, et al. Genetic studies of pathological gambling: a review of methodology and analyses of data from the Vietnam Era Twin Registry. J Gambl Stud. 2005;21(2): 179-203.
87. Comings DE, Gade-Andavolu R, Gonzalez N, et al. The additive effect of neurotransmitter genes in pathological gambling. Clin Genet. 2001;60(2): 107-116.
88. Sabbatini Da Silva Lobo D, Vallada H, Knight J, et al. Dopamine genes and pathological gambling in discordant sib-pairs. J Gambl Stud. 2007;23(4): 421-433.
89. Comings DE, Rosenthal RJ, Lesieur HR, et al. A study of the dopamine D2 receptor gene in pathological gambling. Pharmacogenetics. 1996;6(3): 223-234.
90. Comings DE, Gade R, Wu S, et al. Studies of the potential role of the dopamine D1 receptor gene in addictive behaviors. Mol Psychiatry. 1997;2(1): 44-56.
91. Comings DE, Gonzalez N, Wu S, et al. Studies of the 48 bp repeat polymorphism of the DRD4 gene in impulsive, compulsive, addictive behaviors: Tourette syndrome, ADHD, pathological gambling, and substance abuse. Am J Med Genet. 1999;88(4): 358-368.
92. Pérez De Castro I, Ibáñez A, Torres P, et al. Genetic association study between pathological gambling and a functional DNA polymorphism at the D4 receptor gene. Pharmacogenetics. 1997;7(5): 345-348.
93. Lim S, Ha J, Choi S-W, et al. Association study on pathological gambling and polymorphisms of dopamine D1, D2, D3, and D4 receptor genes in a Korean population. J Gambl Stud. 2012;28(3): 481-491.
94. De Castro IP, Ibánez A, Saiz-Ruiz J, et al. Genetic contribution to pathological gambling: possible association between a functional DNA polymorphism at the serotonin transporter gene (5-HTT) and affected men. Pharmacogenet Genomics. 1999;9(3): 397-400.
95. Ibañez A, Perez De Castro I, Fernandez-Piqueras J, et al. Pathological gambling and DNA polymorphic markers at MAO-A and MAO-B genes. Mol Psychiatry. 2000;5(1): 105-109.
96. De Castro IP, Ibanez A, Saiz-Ruiz J, et al. Concurrent positive association between pathological gambling and functional DNA polymorphisms at the MAO-A and the 5-HT transporter genes. Mol Psychiatry. 2002;7: 927-928.
97. Liu J, Gao XP, Osunde I, et al. Increased regional homogeneity in internet addiction disorder: a resting state functional magnetic resonance imaging study. Chin Med J (Engl). 2010;123(14): 1904-1908.
98. Kim SH, Baik SH, Park CS, et al. Reduced striatal dopamine D2 receptors in people with Internet addiction. Neuroreport. 2011;22(8): 407-411.
99. Lin F, Zhou Y, Du Y, et al. Abnormal white matter integrity in adolescents with internet addiction disorder: a tract-based spatial statistics study. PLoS One. 2012;7(1):e30253.
100. Zhou Y, Lin FC, Du YS, et al. Gray matter abnormalities in Internet addiction: a voxel-based morphometry study. Eur J Radiol. 2011;79(1): 92-95.
101. Yuan K, Qin W, Wang G, et al. Microstructure abnormalities in adolescents with internet addiction disorder. PLoS One. 2011;6(6):e20708.
102. Hou H, Jia S, Hu S, et al. Reduced striatal dopamine transporters in people with internet addiction disorder. J Biomed Biotechnol. 2012;2012:854524. doi: 10.1155/2012/854524. Epub 2012 Mar 13.
103. Lee YS, Han DH, Yang KC, et al. Depression like characteristics of 5HTTLPR polymorphism and temperament in excessive internet users. J Affect Disord. 2008;109(1-2): 165-169.
104. Park HS, Kim SH, Bang SA, et al. Altered regional cerebral glucose metabolism in internet game overusers: a 18F-fluorodeoxyglucose positron emission tomography study. CNS Spectr. 2010;15(3): 159-166.
105. Ko CH, Liu GC, Hsiao S, et al. Brain activities associated with gaming urge of online gaming addiction. J Psychiatr Res. 2009;43(7): 739-747.
106. Ko CH, Liu GC, Yen JY, et al. Brain correlates of craving for online gaming under cue exposure in subjects with Internet gaming addiction and in remitted subjects. Addict Biol. 2011 Oct 26; Epub ahead of print.
107. Han DH, Kim YS, Lee YS, et al. Changes in cue-induced, prefrontal cortex activity with video-game play. Cyberpsychol Behav Soc Netw. 2010;13(6): 655-661.
108. Dong G, Huang J, Du X. Enhanced reward sensitivity and decreased loss sensitivity in Internet addicts: an fMRI study during a guessing task. J Psychiatr Res. 2011;45(11): 1525-1529.
109. Han DH, Lyoo IK, Renshaw PF. Differential regional gray matter volumes in patients with on-line game addiction and professional gamers. J Psychiatr Res. 2012;46(4): 507-515.
110. Han DH, Lee YS, Yang KC, et al. Dopamine genes and reward dependence in adolescents with excessive internet video game play. J Addict Med. 2007;1(3): 133-138.
111. Yoshimoto K, Mcbride WJ, Lumeng L, et al. Alcohol stimulates the release of dopamine and serotonin in the nucleus accumbens. Alcohol. 1992;9(1): 17-22.
112. Raab G, Elger C, Neuner M, et al. A neurological study of compulsive buying behaviour. J Consum Policy. 2011;34(4): 401-413.
113. Knutson B, Rick S, Wimmer GE, et al. Neural predictors of purchases. Neuron. 2007;53(1): 147-156.
114. Koran LM, Bullock KD, Hartston HJ, et al. Citalopram treatment of compulsive shopping: an open-label study. J Clin Psychiatry. 2002;63(8): 704-708.
115. Koran LM, Chuong HW, Bullock KD, et al. Citalopram for compulsive shopping disorder: an open-label study followed by double-blind discontinuation. J Clin Psychiatry. 2003;64(7): 793-798.
116. Black DW, Gabel J, Hansen J, et al. A double-blind comparison of fluvoxamine versus placebo in the treatment of compulsive buying disorder. Ann Clin Psychiatry. 2000;12(4): 205-211.
117. Ninan PT, Mcelroy SL, Kane CP, et al. Placebo-controlled study of fluvoxamine in the treatment of patients with compulsive buying. J Clin Psychopharmacol. 2000;20(3): 362-366.
118. Koran LM, Aboujaoude EN, Solvason B, et al. Escitalopram for compulsive buying disorder: a double-blind discontinuation study. J Clin Psychopharmacol. 2007;27(2): 225-227.
119. Mcelroy SL, Phillips KA, Keck PE Jr. Obsessive compulsive spectrum disorder. J Clin Psychiatry. 1994;55(Suppl): 33-51; discussion 52-53.
120. Black DW, Repertinger S, Gaffney GR, et al. Family history and psychiatric comorbidity in persons with compulsive buying: preliminary findings. Am J Psychiatry. 1998;155(7): 960-963.
121. Devor EJ, Magee HJ, Dill-Devor RM, et al. Serotonin transporter gene (5-HTT) polymorphisms and compulsive buying. Am J Med Genet. 1999;88(2): 123-125.
122. Grant JE, Correia S, Brennan-Krohn T. White matter integrity in kleptomania: a pilot study. Psychiatry Res. 2006;147(2-3): 233-237.
123. Grant JE, Odlaug BL, Kim SW. Kleptomania: clinical characteristics and relationship to substance use disorders. Am J Drug Alcohol Abuse. 2010;36(5): 291-295.
124. Marazziti D, Presta S, Pfanner C, et al. The biological basis of kleptomania and compulsive buying. Scientific Abstracts, American College of Neuropsychopharmacology 39th Annual Meeting. San Juan, Puerto Rico: ACNP; 2000.
125. Koran LM, Aboujaoude EN, Gamel NN. Escitalopram treatment of kleptomania: an open-label trial followed by double-blind discontinuation. J Clin Psychiatry. 2007;68(3): 422-427.
126. Grant JE, Kim SW, Odlaug BL. A double-blind, placebo-controlled study of the opiate antagonist, naltrexone, in the treatment of kleptomania. Biol Psychiatry. 2009;65(7): 600-606.
127. Grant JE, Kim KW. Clinical characteristics and associated psychopathology of 22 patients with kleptomania. Compr Psychiatry. 2002;43(5): 378-384.
128. Mcelroy SL, Hudson JI, Pope H, et al. The DSM-III-R impulse control disorders not elsewhere classified: clinical characteristics and relationship to other psychiatric disorders. Am J Psychiatry. 1992;149(3): 318-327.
129. Miner MH, Raymond N, Mueller BA, et al. Preliminary investigation of the impulsive and neuroanatomical characteristics of compulsive sexual behavior. Psychiatry Res. 2009;174(2): 146-151.
130. Wainberg ML, Muench F, Morgenstern J, et al. A double-blind study of citalopram versus placebo in the treatment of compulsive sexual behaviors in gay and bisexual men. J Clin Psychiatry. 2006;67(12): 1968-1973.
131. Schneider JP, Schneider BH. Couple recovery from sexual addiction: research findings of a survey of 88 marriages. Sex Addict Compulsivity. 1996;3: 111-126.
132. McQueeny T, Schweinsburg BC, Schweinsburg AD, et al. Altered white matter integrity in adolescent binge drinkers. Alcohol Clin Exp Res. 2009;33(7): 1278-1285.
133. Pfefferbaum A, Sullivan EV, Hedehus M, et al. In vivo detection and functional correlates of white matter microstructural disruption in chronic alcoholism. Alcohol Clin Exp Res. 2000;24(8): 1214-1221.
134. Goldstein RZ, Alia-Klein N, Tomasi D, et al. Is decreased prefrontal cortical sensitivity to monetary reward associated with impaired motivation and self-control in cocaine addiction? Am J Psychiatry. 2007;164(1): 43-51.
135. Goldstein RZ, Tomasi D, Rajaram S, et al. Role of the anterior cingulate and medial orbitofrontal cortex in processing drug cues in cocaine addiction. Neuroscience. 2007;144(4): 1153-1159.
136. Potenza MN, Leung H-C, Blumberg HP, et al. An fMRI Stroop task study of ventromedial prefrontal cortical function in pathological gamblers. Am J Psychiatry. 2003;160(11): 1990-1994.
137. Beck A, Schlagenhauf F, Wüstenberg T, et al. Ventral striatal activation during reward anticipation correlates with impulsivity in alcoholics. Biol Psychiatry. 2009;66(8): 734-742.
138. Hommer D, Bjork J, Knutson B, et al. Motivation in children of alcoholics. Alcohol Clin Exp Res. 2004;28:22A.
139. Peters J, Bromberg U, Schneider S, et al. Lower ventral striatal activation during reward anticipation in adolescent smokers. Am J Psychiatry. 2011;168: 540-549.
140. Wrase J, Schlagenhauf F, Kienast T, et al. Dysfunction of reward processing correlates with alcohol craving in detoxified alcoholics. Neuroimage. 2007;35(2): 787-794.
141. Jia Z, Worhunsky PD, Carroll KM, et al. An initial study of neural responses to monetary incentives as related to treatment outcome in cocaine dependence. Biol Psychiatry. 2011;70(6): 553-560.
142. Nestor L, Hester R, Garavan H. Increased ventral striatal BOLD activity during non-drug reward anticipation in cannabis users. Neuroimage. 2010;49(1): 1133-1143.
143. Volkow ND, Wang G-J, Telang F, et al. Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction. J Neurosci. 2006;26(24): 6583-6588.
144. Vollstädt-Klein S, Wichert S, Rabinstein J, et al. Initial, habitual and compulsive alcohol use is characterized by a shift of cue processing from ventral to dorsal striatum. Addiction. 2010;105(10): 1741-1749.
145. Shi J, Zhao LY, Copersino ML, et al. PET imaging of dopamine transporter and drug craving during methadone maintenance treatment and after prolonged abstinence in heroin users. Eur J Pharmacol. 2008;579(1-3): 160-166.
146. Volkow ND, Fowler JS, Wang G-J. The addicted human brain: insights from imaging studies. J Clin Invest. 2003;111(10): 1444-1451.
147. Schlaepfer TE, Pearlson GD, Wong DF, et al. PET study of competition between intravenous cocaine and [C-11]raclopride at dopamine receptors in human subjects. Am J Psychiatry. 1997;154(9): 1209-1213.
148. Ritz M, Lamb R, Goldberg, et al. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science. 1987;237(4819): 1219-1223.
149. Crits-Christoph P, Newberg A, Wintering N, et al. Dopamine transporter levels in cocaine dependent subjects. Drug Alcohol Depend. 2008;98(1-2): 70-76.
150. Volkow ND. Opioid-dopamine interactions: implications for substance use disorders and their treatment. Biol Psychiatry. 2010;68(8):685.
151. Fils-Aime ML, Eckardt MJ, George DT, et al. Early-onset alcoholics have lower cerebrospinal fluid 5-hydroxyindoleacetic acid levels than late-onset alcoholics. Arch Gen Psychiatry. 1996;53(3): 211-216.
152. Ratsma JE, Van Der Stelt O, Gunning WB. Neurochemical markers of alcoholism vulnerability in humans. Alcohol Alcohol. 2002;37(6): 522-533.
153. Coiro V, Vescovi PP. Persistence of defective serotonergic and GABAergic controls of growth hormone secretion in long-term abstinent alcoholics. Alcohol Alcohol. 1997;32(1): 85-90.
154. Bender S, Scherbaum N, Soyka M, et al. The efficacy of the dopamine D2/D3 antagonist tiapride in maintaining abstinence: a randomized, double-blind, placebo-controlled trial in 299 alcohol-dependent patients. Int J Neuropsychopharmacol. 2007;10(5): 653-660.
155. Kampman KM, Pettinati H, Lynch KG, et al. A pilot trial of olanzapine for the treatment of cocaine dependence. Drug Alcohol Depend. 2003;70(3): 265-273.
156. Shaw GK, Waller S, Majumdar SK, et al. Tiapride in the prevention of relapse in recently detoxified alcoholics. Br J Psychiatry. 1994;165(4): 515-523.
157. Amato L, Minozzi S, Pani PP, et al. Antipsychotic medications for cocaine dependence. Cochrane Database Syst Rev. 2007(3):CD006306.
158. Guardia J, Segura L, Gonzalvo B, et al. A double-blind, placebocontrolled study of olanzapine in the treatment of alcoholdependence disorder. Alcohol Clin Exp Res. 2004;28(5): 736-745.
159. Torrens M, Fonseca F, Mateu G, et al. Efficacy of antidepressants in substance use disorders with and without comorbid depression: a systematic review and meta-analysis. Drug Alcohol Depend. 2005;78(1): 1-22.
160. Lobmaier P, Kornør H, Kunøe N, et al. Sustained-release naltrexone for opioid dependence. Cochrane Database Syst Rev. 2008;(2):CD006140.
161. Minozzi S, Amato L, Vecchi S, et al. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev. 2011;(4):CD001333.
162. Rösner S, Hackl-Herrwerth A, Leucht S, et al. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2010;(12):CD001867.
163. Larowe SD, Mardikian P, Malcolm R, et al. Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. Am J Addict. 2006;15(1): 105-110.
164. Krupitsky EM, Neznanova O, Masalov D, et al. Effect of memantine on cue-induced alcohol craving in recovering alcohol-dependent patients. Am J Psychiatry. 2007;164(3): 519-523.
165. Jobes M, Ghitza U, Epstein D, et al. Clonidine blocks stress-induced craving in cocaine users. Psychopharmacology. 2011;218(1): 83-88.
166. Shaham Y, Erb S, Stewart J. Stress-induced relapse to heroin and cocaine seeking in rats: a review. Brain Res Rev. 2000;33(1): 13-33.
167. Sinha R, Kimmerling A, Doebrick C, et al. Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings. Psychopharmacology. 2007;190(4): 569-574.
168. Kreek MJ, Nielsen DA, Butelman ER, et al. Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. Nat Neurosci. 2005;8(11): 1450-1457.
169. Han DH, Hwang JW, Renshaw PF. Bupropion sustained release treatment decreases craving for video games and cue-induced brain activity in patients with Internet video game addiction. Exp Clin Psychopharmacol. 2010;18(4): 297-304.
170. Kilts CD, Schweitzer JB, Quinn CK, et al. Neural activity related to drug craving in cocaine addiction. Arch Gen Psychiatry. 2001;58(4): 334-341.
171. Dom G, Sabbe B, Hulstijn W, et al. Substance use disorders and the orbitofrontal cortex: systematic review of behavioural decision-making and neuroimaging studies. Br J Psychiatry. 2005;187: 209-220.
172. Wilson SJ, Sayette MA, Fiez JA. Prefrontal responses to drug cues: a neurocognitive analysis. Nat Neurosci. 2004;7(3): 211-214.
173. Volkow ND, Fowler JS, Wang GJ, et al. Dopamine in drug abuse and addiction: results of imaging studies and treatment implications. Arch Neurol. 2007;64(11): 1575-1579.
174. Miedl SF, Peters J, Buchel C. Altered neural reward representations in pathological gamblers revealed by delay and probability discounting. Arch Gen Psychiatry. 2012;69(2): 177-186.